

16 August 2019

September 2019 Pharmaceutical Schedule Dispatch

This dispatch email is provided to pharmacists as an early notification of the changes to be announced in the **September 2019** Update to the Pharmaceutical Schedule.

New listings

- Amiodarone hydrochloride (Max Health) inj 50 mg per ml, 3 ml ampoule – up to 6 inj available on a PSO (p'code 2565129)
- Carmustine (Bicnu Heritage) inj 100 mg vial – PCT only – Specialist (p'code 2573768)
- Cilazapril (Zapril) tab 2.5 mg (p'code 2379082) and 5 mg (p'code 2379090)
- Flecainide acetate (Flecainide BNM) tab 50 mg – Retail pharmacy-Specialist (p'code 2567695)
- Levodopa with carbidopa (Mylan) tab long-acting 200 mg with carbidopa 50 mg – S29 and wastage claimable (p'code 2566176)
- Oxaliplatin (Oxaliplatin Accord) inj 5 mg per ml, 20 ml vial – PCT only – Specialist (p'code 2571242)
- Pharmacy services (BSF Mylan Efavirenz Emtricitabine Tenofovir) brand switch fee – may only be claimed once per patient (p'code 2573873)
- Pharmacy services (BSF Teva Atazanavir Sulphate) brand switch fee – may only be claimed once per patient (p'code 2573857)
- Pharmacy services (BSF Teva Emtricitabine Tenofovir Disoproxil) brand switch fee – may only be claimed once per patient (p'code 2573865)
- Raltegravir potassium (Isentress HD) tab 600 mg – Special Authority – Retail pharmacy (p'code 2562960)
- Tacrolimus (Tacrolimus Sandoz) cap 0.75 mg – Special Authority – Retail pharmacy (p'code 2573938)
- Temozolomide (Apo-Temozolomide) cap 20 mg (p'code 2572311) and 100 mg (p'code 2572338) – Special Authority – Retail pharmacy
- Water (Fresenius Kabi) inj 20 ml ampoule – up to 5 inj available on a PSO (p'code 2565692)

Changes to restrictions, chemical names and presentations

- Adalimumab inj 20 mg per 0.4 ml prefilled syringe and 40 mg per 0.8 ml prefilled syringe (Humira) and inj 40 mg per 0.8 ml prefilled pen (HumiraPen) – amended Special Authority criteria
- Atazanavir sulphate (Teva) cap 150 mg and 200 mg – addition of brand switch fee
- Efavirenz with emtricitabine and tenofovir disoproxil (Mylan) tab 600 mg with emtricitabine 200 mg and tenofovir disoproxil 245 mg (300 mg as a maleate) – addition of brand switch fee

- Emtricitabine with tenofovir disoproxil (Teva) tab 200 mg with tenofovir disoproxil 245 mg (300.6 mg as a succinate) – addition of brand switch fee
- Erythromycin (as lactobionate) (Erythrocin IV) inj 1 g vial – amended chemical name and presentation description
- Infliximab inj 100 mg (Remicade) and inj 1 mg for ECP (Baxter) – amended Special Authority criteria
- Sildenafil (Vedafil) tab 25 mg, 50 mg and 100 mg – amended Special Authority criteria
- Sodium chloride inj 0.9%, bag (Baxter), inj 23.4% (4mmol.ml), 20 ml ampoule (Biomed), inj 0.9%, 5 ml ampoule (Fresenius Kabi, InterPharma and Multichem), inj 0.9%, 10 ml ampoule (Fresenius Kabi and Pfizer) and inj 0.9%, 20 ml ampoule (Fresenius Kabi, Multichem and InterPharma) – amended note

Increased subsidy

Chemical	Presentation	Fully subsidised brands
Chlorpheniramine maleate	Oral liq 2 mg per 5 ml, 500 ml	Histafen
Clarithromycin	Grans for oral liq 250 mg per 5 ml, 50 ml	Klacid
Medroxyprogesterone acetate	Inj 150 mg per ml, 1 ml syringe	Depo-Provera
Phenytoin sodium	Tab 50 mg Cap 30 mg and 100 mg	Dilantin Infatab Dilantin
Povidone iodine	Antiseptic soln 10%, 100 ml	Riodine
Pyrimethamine	Tab 25 mg	Daraprim
Sulfasalazine	Tab EC 500 mg	Salazopyrin EN
Sumatriptan	Inj 12 mg per ml, 0.5 ml prefilled pen, 2 OP	Clustran

Decreased subsidy

Chemical	Presentation	Fully subsidised brands	Partially subsidised brands
Chlortalidone [chlorthalidone]	Tab 25 mg	Hygroton	
Erythromycin (as lactobionate)	Inj 1 g vial	Erythrocin IV	
Nicorandil	Tab 10 mg and 20 mg	Ikorel	
Tacrolimus	Cap 0.5 mg, 1 mg and 5 mg	Tacrolimus Sandoz	